financetom
Business
financetom
/
Business
/
Analysis-Wall Street's top regulator faces worsening battle in wake of Supreme Court ruling
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Analysis-Wall Street's top regulator faces worsening battle in wake of Supreme Court ruling
Jun 28, 2024 12:50 PM

WASHINGTON (Reuters) - The Supreme Court's move to curb federal agency powers could curtail efforts by the U.S. Securities and Exchange Commission to establish new rules to police Wall Street and invite more litigation, legal experts said in the wake of Friday's landmark ruling.

The court overturned a 1984 precedent that had given deference to government agencies in interpreting laws they administer. The decision raises the specter of fresh grounds on which to challenge the markets watchdog in court as it rolls out new policies or seeks to regulate new corners of the markets.

The SEC is already fending off an increasing legal assault from public companies, major Wall Street firms and well-heeled cryptocurrency players.

The SCOTUS decision, made 6-3, is likely to tie the SEC's hands as it rolls out new rules, according to half a dozen legal experts.

The SEC did not respond to a request for comment. SEC Chair Gary Gensler told Reuters this month that the agency pivots as required by courts' interpretation of the law.

The ruling is a "game-changer," said Richard Hong, a former SEC trial lawyer and partner with the Morrison Cohen law firm.

The SEC will likely have more reason to pause before acting when seeking to police new financial instruments, said Cary Coglianese, a law professor at the University of Pennsylvania who specializes in regulation.

"It will make it more difficult for agencies to adapt their understandings of statutes in the face of new circumstances," Coglianese said.

The precedent, known as the Chevron deference after a ruling involving the U.S. oil company, had been cited by the SEC and other agencies in prior court cases to justify new regulatory efforts, as they deemed the activities within their purview. But now it would fall solely to a court to determine if the agency is acting within the law, which experts said could have a chilling effect.

Proponents of the approach argue that the Chevron deference allows federal regulatory bodies to adapt to changing times and circumstances. But the Chevron doctrine has come under growing criticism from conservatives, arguing it allows rule-writers to overstep their legal authorities.

While the SEC and other regulators have other tools on which to lean, Chevron has been a bedrock of agency rulemaking.

Between 2003 and 2013, Chevron was applied 66.7% of the time when litigating SEC rules in circuit courts and in those cases the agency won just over 81%, according to 2017 research published in the Michigan Law Review.

"Going forward, agency action will be under even greater scrutiny and there will likely be more opportunities for the regulated community to challenge agency rules and adjudications," said Varu Chilakamarri, a partner at K&L Gates.

Friday's ruling is the latest effort of the conservative "war on the administrative state", which aims to weaken federal agencies across the board. Gensler's ambitious agenda has made the agency, which oversees around 40,000 entities, a top target.

The SEC stayed this year's landmark climate disclosure rule due to legal challenges. A federal appeals court this month struck down its overhaul of private fund oversight on the grounds the agency exceeded its authorities.

"The challenge to the SEC's climate rule was already poised to be a difficult fight for the agency," said Leah Malone, leader of Simpson Thacher's ESG and sustainability practice. Friday's shift "raises even further questions about the survival of the climate rule, as well as other pending rule proposals that have been in the spotlight," Malone said.

Friday's ruling is the second blow to the SEC's authority in as many days from the Supreme Court. On Thursday, the justices ruled the agency's reliance on in-house courts to handle enforcement cases was unconstitutional.

"If yesterday's decision was causing tremors, causing some dishes to tumble out from the cupboards, today's case is a Richter-7 earthquake," said Hong.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Intuitive Surgical Insider Sold Shares Worth $435,000, According to a Recent SEC Filing
Intuitive Surgical Insider Sold Shares Worth $435,000, According to a Recent SEC Filing
Nov 13, 2025
01:58 PM EST, 11/13/2025 (MT Newswires) -- Craig H Barratt, Director, on November 12, 2025, sold 750 shares in Intuitive Surgical ( ISRG ) for $435,000. Following the Form 4 filing with the SEC, Barratt has control over a total of 27,198 common shares of the company, with 27,198 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1035267/000127762025000008/xslF345X05/edgardoc.xml Price: 568.86, Change: -3.60, Percent Change:...
Serve Robotics Shares Skid: What's Going On?
Serve Robotics Shares Skid: What's Going On?
Nov 13, 2025
Serve Robotics Inc ( SERV ) shares are trading lower on Thursday. The company disclosed its financial results for the third quarter. SERV is underperforming relative to peers. Get the market research here. What To Know: Serve Robotics ( SERV ) reported quarterly losses of 40 cents per share, versus the analyst consensus estimate for losses of 33 cents per share....
Turning Vision Into Value: Cie Portfolio Win as Nativo Is Acquired for $120M
Turning Vision Into Value: Cie Portfolio Win as Nativo Is Acquired for $120M
Nov 13, 2025
IRVINE, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Cie, a venture studio, announced today that its portfolio company Nativo, a leading advertising technology provider, has entered into a definitive agreement to be acquired by Life360 ( LIF ) . The transaction, valued at approximately $120 million in cash and stock, marks another successful outcome of Cie’s venture studio model. Nativo joins...
Gilead's One-Pill HIV Treatment Shows Promise In Late-Stage Trial
Gilead's One-Pill HIV Treatment Shows Promise In Late-Stage Trial
Nov 13, 2025
Gilead Sciences Inc ( GILD ). on Thursday shared topline results from the Phase 3 ARTISTRY-1 trial. The open-label trial evaluated the treatment responses of HIV patients who are virologically suppressed switching from a multi-tablet regimen to an investigational single-tablet regimen of bictegravir 75 mg/lenacapavir 50 mg (BIC/LEN). • GILD shares are testing new highs. Check the market position here....
Copyright 2023-2026 - www.financetom.com All Rights Reserved